 A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein NS5A resistance-associated variants. Daclatasvir 60mgday and asunaprevir 100 mg twice daily plus weight-based ribavirin 1000-1200 mgd for 12 weeks will be prescribed. 